CNS vs CRVO: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
CNS (Cohen & Steers) and CRVO (CervoMed) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
CNS vs CRVO: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CNS | CRVO | What it tells you |
|---|---|---|---|
| Forward P/E | 21.15 | -1.03 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.22 | -4.42 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 90% of range | 5% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 7.51 | 2.25 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how CNS and CRVO affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and CRVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and CRVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Cohen & Steers (CNS) do?
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).
What does CervoMed (CRVO) do?
CervoMed is a clinical-stage biopharmaceutical company developing neflamapimod, an oral small-molecule inhibitor of p38 MAP kinase alpha, which the company says targets the neuroinflammation and synaptic dysfunction that drive neurodegenerative disease. Its lead program is in dementia with Lewy bodies (DLB), a common and serious form of dementia with few approved treatments. CervoMed is also exploring neflamapimod in additional indications such as frontotemporal disorders, nonfluent variant primary progressive aphasia, and recovery-related neurology programs, but DLB is the central driver of the story.
CNS vs CRVO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.
- CRVO drivers: Differentiated mechanism in a high-unmet-need disease; Supportive secondary and biomarker data.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For CRVO, cervoMed is an extremely speculative micro-cap with no approved products and no product revenue, so its fate hinges on a single asset, neflamapimod, in a disease where its pivotal Phase 2b already missed its primary endpoint.
CNS or CRVO: which should you pick?
CNS vs CRVO: the full fundamentals
CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.
CRVO. A single-asset clinical biotech like CervoMed cannot be valued on earnings, revenue, or P/E because it has none; its market value reflects a probability-weighted guess at neflamapimod's eventual commercial potential, discounted heavily for trial and financing risk. The variables that matter most are catalyst outcomes (the planned Phase 3 and partnering efforts), the cash runway, and how much dilution future raises will impose. With a going-concern flag and a limited runway, financing terms can swing the share count and the implied value as much as the science does.
Headline figures (approximate, APRIL 2026): CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82; CRVO shows product revenue None (clinical-stage; grant revenue lapsed to $0), net loss (q1 2026) ~$8.0 million, cash & equivalents ~$12.9 million (Q1 2026), cash runway Into Q3 2026; extended into Q2 2027 after ~$10.5M June 2026 placement.
The bottom line: CNS vs CRVO
CNS and CRVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNS and CRVO exposure against your real portfolio. It is not an investment adviser.
Wondering how CNS or CRVO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Cohen & Steers with AI
Connect the broker you already use and ask Walnut's AI how CNS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CNS and CRVO?
+
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. CervoMed is a clinical-stage biopharmaceutical company developing neflamapimod, an oral small-molecule inhibitor of p38 MAP kinase alpha, which the company says targets the neuroinflammation and synaptic dysfunction that drive neurodegenerative disease. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CNS or CRVO the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CNS or CRVO?
+
On forward P/E (as of August 2026), CNS trades at 21.15x and CRVO at -1.03x, so CRVO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CNS and CRVO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CNS vs CRVO?
+
CNS: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter. CRVO: CervoMed is an extremely speculative micro-cap with no approved products and no product revenue, so its fate hinges on a single asset, neflamapimod, in a disease where its pivotal Phase 2b already missed its primary endpoint. Outcomes are binary: a failed or delayed Phase 3, a regulatory setback, or an inability to secure a partner could sharply reduce or wipe out the value. Management has flagged substantial doubt about the company's ability to continue as a going concern, and even after a June 2026 financing the runway is limited, so further capital raises are likely and could heavily dilute existing shareholders. Single-asset concentration, ongoing losses, and reliance on external financing make the stock high-risk and capable of total loss.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CNS or CRVO; figures are approximate and dated (as of August 2026). Verify current data before investing.